NO981557L - Influensavaksine - Google Patents

Influensavaksine

Info

Publication number: NO981557L
Authority: NO; Norway
Prior art keywords: influenza vaccine; influenza; vaccine
Prior art date: 1997-04-09

Application number

NO981557A

Other languages

English (en)

Other versions

NO981557D0 (no

NO323349B1 (no

Inventor

Gustaaf J M Van Scharrenburg

Rudi Brands

Original Assignee

Duphar Int Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-09

Filing date

1998-04-06

Publication date

1998-10-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8228174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO981557(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-04-06 Application filed by Duphar Int Res filed Critical Duphar Int Res

1998-04-06 Publication of NO981557D0 publication Critical patent/NO981557D0/no

1998-10-12 Publication of NO981557L publication Critical patent/NO981557L/no

2007-04-02 Publication of NO323349B1 publication Critical patent/NO323349B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16051—Methods of production or purification of viral material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

NO981557A 1997-04-09 1998-04-06 Influensaoverflateantigenvaksine samt fremgangsmåte for å fremstille nevnte vaksine. NO323349B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP97201007		1997-04-09

Publications (3)

Publication Number	Publication Date
NO981557D0 NO981557D0 (no)	1998-04-06
NO981557L true NO981557L (no)	1998-10-12
NO323349B1 NO323349B1 (no)	2007-04-02

Family

ID=8228174

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO981557A NO323349B1 (no)	1997-04-09	1998-04-06	Influensaoverflateantigenvaksine samt fremgangsmåte for å fremstille nevnte vaksine.

Country Status (32)

Country	Link
US (1)	US5948410A (no)
EP (1)	EP0870508B1 (no)
JP (1)	JP5258127B2 (no)
KR (1)	KR100593235B1 (no)
CN (1)	CN1138564C (no)
AR (1)	AR011216A1 (no)
AT (1)	ATE197406T1 (no)
AU (1)	AU728939B2 (no)
BR (1)	BR9801015A (no)
CA (1)	CA2234208C (no)
CZ (1)	CZ297492B6 (no)
DE (2)	DE69800383T2 (no)
DK (1)	DK0870508T3 (no)
DZ (1)	DZ2462A1 (no)
ES (1)	ES2129386T3 (no)
GR (2)	GR990300017T1 (no)
HK (1)	HK1010833A1 (no)
HR (1)	HRP980187B1 (no)
HU (1)	HUP9800802A3 (no)
ID (1)	ID20399A (no)
IL (1)	IL123961A (no)
NO (1)	NO323349B1 (no)
NZ (1)	NZ330131A (no)
PL (1)	PL187982B1 (no)
PT (1)	PT870508E (no)
RU (1)	RU2197264C2 (no)
SI (1)	SI0870508T1 (no)
SK (1)	SK282614B6 (no)
TR (1)	TR199800613A1 (no)
TW (1)	TW570803B (no)
UA (1)	UA42089C2 (no)
ZA (1)	ZA982915B (no)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60036952T2 (de) *	1999-09-24	2008-08-07	Glaxosmithkline Biologicals S.A.	Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
GB9923176D0 (en) *	1999-09-30	1999-12-01	Smithkline Beecham Biolog	Novel composition
CN100415769C (zh) *	2002-02-07	2008-09-03	中国科学院过程工程研究所	寡聚或多聚亚基蛋白质分离纯化的方法
AU2003229159B2 (en)	2002-04-30	2008-02-21	Oncolytics Biotech Inc.	Improved viral purification methods
US20060110406A1 (en) *	2003-02-25	2006-05-25	Medimmune Vaccines, Inc.	Refrigerator-temperature stable influenza vaccine compositions
KR101190932B1 (ko)	2003-02-25	2012-10-16	메디뮨 엘엘씨	인플루엔자 백신 조성물의 제조 방법
WO2004113518A1 (en) *	2003-06-20	2004-12-29	Microbix Biosystems Inc.	Improvements in virus production
US8592197B2 (en)	2003-07-11	2013-11-26	Novavax, Inc.	Functional influenza virus-like particles (VLPs)
US8080255B2 (en)	2003-07-11	2011-12-20	Novavax Inc.	Functional influenza virus like particles (VLPs)
US8992939B2 (en)	2003-07-11	2015-03-31	Novavax, Inc.	Highly efficient influenza matrix (M1) proteins
US8506967B2 (en)	2003-07-11	2013-08-13	Novavax, Inc.	Functional influenza virus like particles (VLPs)
EP1780269B1 (en) *	2004-02-23	2009-07-08	Crucell Holland B.V.	Virus purification methods
DE202005022108U1 (de)	2004-03-09	2013-11-12	Novartis Vaccines And Diagnostics, Inc.	Influenza-Virus-Impfstoffe
US8119337B2 (en)	2004-09-09	2012-02-21	Jens-Peter Gregersen	Decreasing potential iatrogenic risks associated with influenza vaccines
US7901921B2 (en)	2004-10-22	2011-03-08	Oncolytics Biotech Inc.	Viral purification methods
JP2008519042A (ja)	2004-11-03	2008-06-05	ノバルティスヴァクシンズアンドダイアグノスティクス，インコーポレイテッド	インフルエンザワクチン接種
DK2368975T3 (en) *	2004-12-23	2015-01-05	Medimmune Llc	Non-tumorigenic MDCK cell line for the propagation of viruses
US20090081253A1 (en)	2005-03-23	2009-03-26	Glaxosmithkline Biologicals S.A.	Composition
WO2006108707A1 (en) *	2005-04-11	2006-10-19	Crucell Holland B.V.	Virus purification using ultrafiltration
PT2301572E (pt) *	2005-11-01	2014-12-22	Novartis Vaccines & Diagnostic	Vacinas virais derivadas de células com níveis baixos de adn celular residual
US11707520B2 (en)	2005-11-03	2023-07-25	Seqirus UK Limited	Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
BRPI0618254A2 (pt)	2005-11-04	2011-08-23	Novartis Vaccines & Diagnostic	emulsões com agente tensoativo de fase aquosa livre para fornecer adjuvante às vacinas contra influenza dividido
EP2368572B1 (en)	2005-11-04	2020-03-04	Seqirus UK Limited	Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ592713A (en)	2005-11-04	2012-12-21	Novartis Vaccines & Diagnostic	Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
US20090304742A1 (en)	2005-11-04	2009-12-10	Novartis Vaccines And Diagnostics Srl	Influenza vaccines with reduced amount of emulsion adjuvant
PT1951299E (pt)	2005-11-04	2012-02-28	Novartis Vaccines & Diagnostic	Vacinas contra a gripe que incluem combinações de adjuvantes particulados e imuno-potenciadores
KR20110110853A (ko) *	2006-01-27	2011-10-07	노파르티스 파르마 아게	적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
JP2009534303A (ja)	2006-03-24	2009-09-24	ノバルティスヴァクシンズアンドダイアグノスティクスゲーエムベーハーアンドカンパニーカーゲー	冷蔵しないインフルエンザワクチンの保存
WO2007126810A2 (en)	2006-03-31	2007-11-08	Warf - Wisconsin Alumni Research Foundation	High titer recombinant influenza viruses for vaccines
WO2008009309A1 (en)	2006-07-17	2008-01-24	Glaxosmithkline Biologicals S.A.	Influenza vaccine
GB0614460D0 (en) *	2006-07-20	2006-08-30	Novartis Ag	Vaccines
AU2007297178B2 (en)	2006-09-11	2014-07-24	Novartis Ag	Making influenza virus vaccines without using eggs
ES2473275T3 (es)	2006-09-15	2014-07-04	Medimmune, Llc	Líneas de células MDCK que soportan el crecimiento viral hasta altos títulos y proceso de biorreactor que las usa.
CA2671629C (en)	2006-12-06	2017-08-15	Novartis Ag	Vaccines including antigen from four strains of influenza virus
PT2114421T (pt) *	2007-03-05	2018-04-17	Om Pharma	Extrato bacteriano para distúrbios respiratórios e processo para a sua preparação
EP2139908A4 (en)	2007-03-12	2011-02-16	Antigen Express Inc	REMOVAL OF PROTEIN Li INVOLVED IN Li-RNAi CONSTRUCTIONS IN ANTICANCER IMMUNOTHERAPY
AR066405A1 (es)	2007-04-20	2009-08-19	Glaxosmithkline Biolog Sa	Vacuna
US9474798B2 (en)	2007-06-18	2016-10-25	Wisconsin Alumni Research Foundation	Influenza M2 protein mutant viruses as live influenza attenuated vaccines
AU2008269439B2 (en)	2007-06-27	2013-12-19	Novartis Ag	Low-additive influenza vaccines
EP3058954B1 (en) *	2007-08-27	2017-03-01	Longhorn Vaccines and Diagnostics, LLC	Immunogenic compositions and methods
GB0810305D0 (en)	2008-06-05	2008-07-09	Novartis Ag	Influenza vaccination
JP5518041B2 (ja)	2008-03-18	2014-06-11	ノバルティスアーゲー	インフルエンザウイルスワクチン抗原の調製における改良
RU2547587C2 (ru) *	2008-09-24	2015-04-10	Медиммун, Ллк	Способы культивирования клеток, размножения и очистки вирусов
WO2010052214A2 (en)	2008-11-05	2010-05-14	Glaxosmithkline Biologicals S.A.	Novel method
CA2752041A1 (en)	2009-02-10	2010-08-19	Novartis Ag	Influenza vaccines with increased amounts of h3 antigen
JP5778039B2 (ja)	2009-02-10	2015-09-16	ノバルティスアーゲー	流行関連株のためのインフルエンザワクチンレジメン
EP3173097A3 (en)	2009-02-10	2017-07-12	Seqirus UK Limited	Influenza vaccines with reduced amounts of squalene
KR20120027276A (ko)	2009-04-27	2012-03-21	노파르티스 아게	인플루엔자를 예방하기 위한 면역증강된 백신
EP2401384B1 (en)	2009-05-21	2012-10-03	Novartis AG	Reverse genetics using non-endogenous pol i promoters
WO2010144797A2 (en)	2009-06-12	2010-12-16	Vaccine Technologies, Incorporated	Influenza vaccines with enhanced immunogenicity and uses thereof
CA2803282C (en)	2009-07-06	2018-05-01	David E. Anderson	Methods for preparing vesicles and formulations produced therefrom
MX2012000372A (es)	2009-07-06	2012-02-28	Variation Biotechnologies Inc	Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
JP2013500712A (ja)	2009-07-31	2013-01-10	ノバルティスアーゲー	逆遺伝学系
BR112012008338A2 (pt)	2009-09-10	2019-09-24	Novartis Ag	combinação de vacinas contra doenças do trato respiratório.
ES2454815T3 (es)	2009-10-20	2014-04-11	Novartis Ag	Métodos mejorados de genética inversa para la recuperación de virus
EP2493912B1 (en)	2009-10-26	2020-07-29	Wisconsin Alumni Research Foundation	High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en)	2010-03-23	2018-11-20	Wisconsin Alumni Research Foundation (Warf)	Vaccines comprising mutant attenuated influenza viruses
WO2011145081A1 (en)	2010-05-21	2011-11-24	Novartis Ag	Influenza virus reassortment method
BR112012030619A2 (pt)	2010-06-01	2019-09-24	Novartis Ag	concentração de antígenos de vacina influenza sem liofilização.
CN102939104A (zh)	2010-06-01	2013-02-20	诺华有限公司	用冻干浓缩疫苗抗原
CA2840079C (en)	2010-07-06	2018-07-03	Variation Biotechnologies Inc.	Compositions and methods for treating influenza
AU2011290471B2 (en)	2010-08-20	2015-08-20	Novartis Ag	Soluble needle arrays for delivery of influenza vaccines
CA2862864C (en)	2011-01-13	2018-12-11	Variation Biotechnologies Inc.	Compositions and methods for treating viral infections
US20130323280A1 (en)	2011-01-13	2013-12-05	Variation Biotechnologies, Inc.	Methods for preparing vesicles and formulations produced therefrom
AU2012324398A1 (en)	2011-10-20	2014-05-01	Seqirus UK Limited	Adjuvanted influenza B virus vaccines for pediatric priming
EP2780350B1 (en)	2011-11-18	2019-03-06	Variation Biotechnologies Inc.	Synthetic derivatives of mpl and uses thereof
CA2894442C (en)	2012-01-12	2020-01-21	Variation Biotechnologies Inc.	Compositions and methods for treating viral infections
RU2698906C2 (ru)	2012-01-27	2019-09-02	Вэриэйшн Биотекнолоджиз, Инк.	Способы и композиции для терапевтических агентов
AU2013205478B9 (en)	2012-03-02	2014-11-20	Seqirus UK Limited	Influenza virus reassortment
JP2015526062A (ja)	2012-06-04	2015-09-10	ノバルティスアーゲー	改善された安全性試験
GB201218195D0 (en)	2012-10-10	2012-11-21	Istituto Zooprofilattico Sperimentale Delle Venezie	Composition
JP6421128B2 (ja)	2012-12-03	2018-11-07	ノバルティスアーゲー	リアソータントインフルエンザａウイルス
CN111334530A (zh)	2013-03-13	2020-06-26	诺华股份有限公司	乙型流感病毒重配
JP2016521282A (ja)	2013-05-10	2016-07-21	ノバルティスアーゲー	インフルエンザワクチンにおけるナルコレプシーのリスクの回避
DE202013005100U1 (de)	2013-06-05	2013-08-26	Novartis Ag	Influenza Virus Reassortierung
DE202013005130U1 (de)	2013-06-05	2013-09-10	Novartis Ag	Influenza Virus Reassortierung
AU2014276418A1 (en)	2013-06-06	2016-01-21	Novartis Ag	Influenza virus reassortment
US9950057B2 (en)	2013-07-15	2018-04-24	Wisconsin Alumni Research Foundation (Warf)	High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
RU2535153C1 (ru) *	2013-09-04	2014-12-10	Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства России (ФГУП СПбНИИВС ФМБА России)	Способ получения высокоочищенных вирионных концентратов
CN105745218B (zh)	2013-11-15	2020-11-06	诺华股份有限公司	去除残留细胞培养杂质
WO2015196150A2 (en)	2014-06-20	2015-12-23	Wisconsin Alumni Research Foundation (Warf)	Mutations that confer genetic stability to additional genes in influenza viruses
EP2966093A1 (en)	2014-07-07	2016-01-13	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Process for the preparation of magnetic sulfated cellulose particles, magnetic sulfated cellulose particles and their use
US10633422B2 (en)	2015-06-01	2020-04-28	Wisconsin Alumni Research Foundation (Warf)	Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
RU2614127C2 (ru) *	2015-06-04	2017-03-22	Общество с ограниченной ответственностью "НТфарма"	Способ получения концентрата рекомбинантных псевдоаденовирусных частиц, экспрессирующих ген гемагглютинина вируса гриппа A/California/07/2009(H1N1)
WO2016207853A2 (en)	2015-06-26	2016-12-29	Seqirus UK Limited	Antigenically matched influenza vaccines
WO2017007839A1 (en)	2015-07-06	2017-01-12	Wisconsin Alumni Research Foundation (Warf)	Improved influenza virus replication for vaccine development
US10416171B2 (en)	2015-07-07	2019-09-17	Seqirus UK Limited	Influenza potency assays
JP2019510481A (ja)	2016-02-19	2019-04-18	ウィスコンシンアルムニリサーチファンデイション	ワクチン開発のための改善されたｂ型インフルエンザウイルス複製
US20200392468A1 (en)	2017-03-30	2020-12-17	Merck Sharp & Dohme Corp.	Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids
RU2670001C1 (ru) *	2017-12-25	2018-10-17	Федеральное государственное бюджетное учреждение науки Институт биохимии и физиологии растений и микроорганизмов Российской академии наук	Способ получения белков клеточной поверхности
AU2019207600B2 (en)	2018-01-09	2025-01-09	Theriva Biologics, Inc.	Alkaline phosphatase agents for treatment of neurodevelopmental disorders
EP3773686B1 (en)	2018-03-20	2023-06-07	Theriva Biologics, Inc.	Alkaline phosphatase agents for treatment of radiation disorders
EP3768302A4 (en)	2018-03-20	2021-12-15	Synthetic Biologics, Inc.	INTESTINAL ALKALINE PHOSPHATASE FORMULATIONS
WO2020041311A1 (en)	2018-08-20	2020-02-27	Wisconsin Alumni Research Foundation	Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein
JP2022527235A (ja)	2019-01-23	2022-06-01	義裕河岡	インフルエンザウイルスにおける付加的遺伝子に遺伝的安定性を付与する突然変異
US11851648B2 (en)	2019-02-08	2023-12-26	Wisconsin Alumni Research Foundation (Warf)	Humanized cell line
CN114929269A (zh)	2019-05-01	2022-08-19	威斯康星校友研究基金会(Warf)	用于疫苗开发的改进的流感病毒复制
JP7627911B2 (ja)	2019-08-27	2025-02-07	ウィスコンシンアルムニリサーチファンデイション	卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス
MX2022006005A (es)	2019-11-18	2022-10-27	Seqirus Pty Ltd	Metodo para producir virus de la influenza reagrupados.
KR102444684B1 (ko) *	2020-04-29	2022-09-16	에스케이바이오사이언스(주)	일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH589453A5 (no) *	1974-01-14	1977-07-15	Sandoz Ag
US4500513A (en) *	1979-05-15	1985-02-19	Miles Laboratories, Inc.	Influenza vaccine production in liquid cell culture
US4317811A (en) *	1980-09-11	1982-03-02	Merck & Co., Inc.	Herpes simplex type 1 subunit vaccine
DE3237313A1 (de) *	1982-10-08	1984-04-12	Werner Heese	Verfahren zur gewinnung und reinigung antigenhaltiger loesungen, insbesondere fuer influenza-viren, aus antigenhaltiger allantoisfluessigkeit
US4783411A (en) *	1984-10-22	1988-11-08	Janis Gabliks	Influenza-A virus vaccine from fish cell cultures
US5173418A (en) *	1985-05-10	1992-12-22	Benzon Pharma, A/S	Production in Escherichia coli of extracellular Serratia spp. hydrolases
US5006472A (en) *	1988-06-03	1991-04-09	Miles Inc.	Enzymatic purification process
RU2080876C1 (ru) *	1989-02-07	1997-06-10	Био-Текнолоджи Дженерал Корп.	Способ получения очищенных частиц поверхностного антигена гепатита в, очищенная частица поверхностного антигена гепатита в человека и вакцина против гепатита в
DE69024392T2 (de) *	1989-03-29	1996-07-25	Univ New York	Verfahren zur Reinigungbvon Aussenmembran-Protein von Haemophilus influenzae
DZ1706A1 (fr) *	1992-08-07	2002-02-17	Merck & Co Inc	Vaccin contre le virus de l'hepatite a.
HRP950097A2 (en) *	1994-03-08	1997-06-30	Merck & Co Inc	Hepatitis a virus culture process
EP0791055B1 (en) *	1994-11-10	2012-01-25	Baxter Healthcare S.A.	Method for producing biologicals in protein-free culture
US5681746A (en) *	1994-12-30	1997-10-28	Chiron Viagene, Inc.	Retroviral delivery of full length factor VIII
CA2228128C (fr) *	1995-08-01	2011-03-29	Pasteur Merieux Serums & Vaccins	Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu
CZ92998A3 (cs) *	1995-09-28	1998-09-16	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Způsob stimulace buněčně zprostředkované imunitní odpovědi pomocí cílené imunizace genovým materiálem vázaným na částicích

1998
- 1998-04-01 TW TW087104913A patent/TW570803B/zh not_active IP Right Cessation
- 1998-04-02 AT AT98201056T patent/ATE197406T1/de active
- 1998-04-02 DE DE69800383T patent/DE69800383T2/de not_active Expired - Lifetime
- 1998-04-02 SI SI9830010T patent/SI0870508T1/xx unknown
- 1998-04-02 PT PT98201056T patent/PT870508E/pt unknown
- 1998-04-02 DK DK98201056T patent/DK0870508T3/da active
- 1998-04-02 EP EP98201056A patent/EP0870508B1/en not_active Revoked
- 1998-04-02 DE DE0870508T patent/DE870508T1/de active Pending
- 1998-04-02 ES ES98201056T patent/ES2129386T3/es not_active Expired - Lifetime
- 1998-04-02 TR TR1998/00613A patent/TR199800613A1/xx unknown
- 1998-04-06 IL IL12396198A patent/IL123961A/xx not_active IP Right Cessation
- 1998-04-06 ZA ZA982915A patent/ZA982915B/xx unknown
- 1998-04-06 KR KR1019980012018A patent/KR100593235B1/ko not_active IP Right Cessation
- 1998-04-06 NZ NZ330131A patent/NZ330131A/en not_active IP Right Cessation
- 1998-04-06 ID IDP980519A patent/ID20399A/id unknown
- 1998-04-06 BR BR9801015-8A patent/BR9801015A/pt not_active Application Discontinuation
- 1998-04-06 NO NO981557A patent/NO323349B1/no not_active IP Right Cessation
- 1998-04-06 PL PL98325722A patent/PL187982B1/pl unknown
- 1998-04-06 RU RU98106860/13A patent/RU2197264C2/ru active
- 1998-04-06 SK SK445-98A patent/SK282614B6/sk not_active IP Right Cessation
- 1998-04-06 US US09/055,321 patent/US5948410A/en not_active Expired - Lifetime
- 1998-04-06 AU AU60659/98A patent/AU728939B2/en not_active Expired
- 1998-04-06 DZ DZ980072A patent/DZ2462A1/xx active
- 1998-04-06 CA CA002234208A patent/CA2234208C/en not_active Expired - Lifetime
- 1998-04-06 CN CNB981080863A patent/CN1138564C/zh not_active Expired - Lifetime
- 1998-04-06 CZ CZ0105098A patent/CZ297492B6/cs unknown
- 1998-04-06 HR HR980187A patent/HRP980187B1/xx not_active IP Right Cessation
- 1998-04-06 HU HU9800802A patent/HUP9800802A3/hu not_active Application Discontinuation
- 1998-04-07 JP JP11010198A patent/JP5258127B2/ja not_active Expired - Lifetime
- 1998-04-08 AR ARP980101611A patent/AR011216A1/es not_active Application Discontinuation
- 1998-04-08 UA UA98041787A patent/UA42089C2/uk unknown
- 1998-11-17 HK HK98112068A patent/HK1010833A1/xx not_active IP Right Cessation
1999
- 1999-01-01 GR GR990300017T patent/GR990300017T1/el unknown
2000
- 2000-11-09 GR GR20000402476T patent/GR3034798T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
HK1010833A1 (en)	1999-07-02
US5948410A (en)	1999-09-07
SK44598A3 (en)	1998-11-04
ZA982915B (en)	1999-01-21
PL325722A1 (en)	1998-10-12
AU6065998A (en)	1998-10-15
CN1196956A (zh)	1998-10-28
KR100593235B1 (ko)	2007-12-04
KR19980081114A (ko)	1998-11-25
BR9801015A (pt)	2000-01-11
GR3034798T3 (en)	2001-02-28
ES2129386T1 (es)	1999-06-16
CZ105098A3 (cs)	1998-10-14
TW570803B (en)	2004-01-11
GR990300017T1 (en)	1999-06-30
MX9802766A (es)	1998-12-31
HRP980187A2 (en)	1999-04-30
NO981557D0 (no)	1998-04-06
IL123961A (en)	2000-07-16
HRP980187B1 (en)	2001-04-30
TR199800613A1 (xx)	1998-10-21
UA42089C2 (uk)	2001-10-15
CA2234208A1 (en)	1998-10-09
CA2234208C (en)	2003-06-10
EP0870508B1 (en)	2000-11-08
PT870508E (pt)	2001-04-30
ID20399A (id)	1998-12-10
ATE197406T1 (de)	2000-11-11
SK282614B6 (sk)	2002-10-08
NO323349B1 (no)	2007-04-02
AU728939B2 (en)	2001-01-18
SI0870508T1 (en)	2001-02-28
ES2129386T3 (es)	2001-01-01
DK0870508T3 (da)	2000-11-20
EP0870508A1 (en)	1998-10-14
CN1138564C (zh)	2004-02-18
RU2197264C2 (ru)	2003-01-27
HUP9800802A2 (hu)	1999-04-28
AR011216A1 (es)	2000-08-02
DE69800383T2 (de)	2001-08-16
DE69800383D1 (de)	2000-12-14
JPH1121253A (ja)	1999-01-26
NZ330131A (en)	1999-10-28
DZ2462A1 (fr)	2003-01-18
CZ297492B6 (cs)	2007-01-03
PL187982B1 (pl)	2004-11-30
JP5258127B2 (ja)	2013-08-07
HUP9800802A3 (en)	2003-08-28
DE870508T1 (de)	1999-08-19
HU9800802D0 (en)	1998-05-28

Publication	Publication Date	Title
ATE197406T1 (de)	2000-11-11	Influenza vaccine
NO20003302D0 (no)	2000-06-23	Vaksine
NO996133D0 (no)	1999-12-10	Olje-i-vann-vaksinesammensetninger
NO20014322L (no)	2001-11-14	Vaksine
BR9711853A (pt)	1999-08-24	Vacinas
NO20006191D0 (no)	2000-12-06	Vaksine
DE69727923D1 (de)	2004-04-08	Gehhilfe
DE60002650D1 (de)	2003-06-18	Öladjuvierter Impfstoff
NO20020763L (no)	2002-04-16	Vaksine
EP0967993A4 (en)	2001-04-18	ANTI-COCAINE VACCINE
DE69826593D1 (de)	2004-11-04	Neospora Impstoff
NO20005599D0 (no)	2000-11-06	Vaksine
DE69820648D1 (de)	2004-01-29	Gehhilfe
ATE431415T1 (de)	2009-05-15	Hiv impfstoff
ID23663A (id)	2000-05-11	Persiapan kaprolaktam
ITMI981384A0 (it)	1998-06-17	Vaccino per hiv
BR1100968A (pt)	2002-04-09	Formulação de vacina de subunidade

Legal Events

Date	Code	Title	Description
2012-08-27	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: ABBOTT BIOLOGICALS BV, NL
2016-04-11	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: BGP PRODUCTS B.V., NL
2018-05-07	MK1K	Patent expired